Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263340, C514S263400
Reexamination Certificate
active
07932263
ABSTRACT:
A combination comprising candesartan and rosuvastatin for the prevention or treatment of arteriosclerosis and for the prevention of cardiovascular events is described.
REFERENCES:
patent: 5196444 (1993-03-01), Naka et al.
patent: 5298497 (1994-03-01), Tschollar et al.
patent: 5328919 (1994-07-01), Naka et al.
patent: 5401764 (1995-03-01), Naka et al.
patent: 5703110 (1997-12-01), Naka et al.
patent: 5705517 (1998-01-01), Naka et al.
patent: 5721263 (1998-02-01), Inada et al.
patent: 5958961 (1999-09-01), Inada et al.
patent: 5962491 (1999-10-01), Naka et al.
patent: 6004989 (1999-12-01), Naka et al.
patent: 6228874 (2001-05-01), Inada et al.
patent: 6232334 (2001-05-01), Naka et al.
patent: 6348481 (2002-02-01), Inada et al.
patent: 6355808 (2002-03-01), Naka et al.
patent: 6420405 (2002-07-01), Inada et al.
patent: 6620821 (2003-09-01), Robl
patent: 6894058 (2005-05-01), Cameron et al.
patent: 2003/0053950 (2003-03-01), Leyland-Jones
patent: 2003/0069221 (2003-04-01), Kosoglou et al.
patent: 2009/0186908 (2009-07-01), Cameron et al.
patent: 2388818 (2001-04-01), None
patent: 0 457 514 (1991-11-01), None
patent: 0 521 471 (1993-01-01), None
patent: 0 628 313 (1994-12-01), None
patent: 0 753 301 (1997-01-01), None
patent: 1 306 088 (2003-05-01), None
patent: 1 306 089 (2003-05-01), None
patent: 1 314 425 (2003-05-01), None
patent: 1314425 (2003-05-01), None
patent: 1673091 (2009-12-01), None
patent: 2361 185 (2001-10-01), None
patent: 2361 186 (2001-10-01), None
patent: 10-81633 (1998-03-01), None
patent: 2002-145770 (2002-05-01), None
patent: 2002145770 (2002-05-01), None
patent: WO 93/08823 (1993-05-01), None
patent: WO 9526188 (1995-05-01), None
patent: WO 95/26188 (1995-10-01), None
patent: WO 97/19917 (1997-06-01), None
patent: WO 97/37688 (1997-10-01), None
patent: WO 99/11260 (1999-03-01), None
patent: WO 99/11263 (1999-03-01), None
patent: WO 00/42024 (2000-07-01), None
patent: WO 00/45817 (2000-08-01), None
patent: WO 00/45818 (2000-08-01), None
patent: WO 00/45819 (2000-08-01), None
patent: WO 00/49014 (2000-08-01), None
patent: WO 00/50007 (2000-08-01), None
patent: WO 00/61551 (2000-10-01), None
patent: WO 01/15674 (2001-03-01), None
patent: WO 01/15744 (2001-03-01), None
patent: WO 01/28555 (2001-04-01), None
patent: WO 01/37808 (2001-05-01), None
patent: WO 01/54669 (2001-08-01), None
patent: WO 01/60804 (2001-08-01), None
patent: WO 01/72706 (2001-10-01), None
patent: WO 01/74394 (2001-10-01), None
patent: WO 01/76573 (2001-10-01), None
patent: WO 02/41895 (2002-05-01), None
patent: WO 02/058731 (2002-08-01), None
patent: WO 03/032995 (2003-04-01), None
patent: WO 2004/096810 (2004-11-01), None
patent: WO 2004096810 (2004-11-01), None
patent: WO 2004/108691 (2004-12-01), None
patent: WO 2005/023779 (2005-03-01), None
patent: WO 2005/028450 (2005-03-01), None
patent: WO 2005/030215 (2005-04-01), None
patent: WO 2005/039638 (2005-05-01), None
patent: WO 2005/042522 (2005-05-01), None
patent: WO 2006/040085 (2006-04-01), None
Qin et al. (Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes, (Kidney International (2003), 64, 565-571, printed pp. 1 and 2, especially p. 1 (please see abstract).
Chen, Jiawei et al. “Marked Upregulation of Lipoxygenase-1, a Receptor for Ox-Low-Density Lipoprotein in Atherosclerosis, and Its Total Ablation by Candesartan and Rosuvastatin Given Concurrently”, Journal of American College of Cardiology, vol. 43, No. 5 (Supplement A) Mar. 3, 2004 p. 498A, (Abstract).
Qin et al. “Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes” Kidney International 64:565-571 (2003).
Beaudeux et al. “The Potential Role of Matrix Metalloproteinases in the Treatment of Atherosclerosis” Annales de Biologie Clinique 61: 147-158 (2003).
Bellosta et al. “HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages” Arteriosclerosis, Thrombosis, and Vascular Biology 18: 1671-1678 (1998).
Bocan et al. “The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits” Arteriosclerosis, Thrombosis, and Vascular Biology 20: 70-79 (2000).
Bocan, T. “Pleiotropic Effects of HMG-CoA Reductase Inhibitors” Current Opinion in Investigational Drugs 3(9:) 1312-1317(2002).
Borghi, C. “Interactions Between Hyopercholesterolemia and Hypertension: Implications for Therapy” Current Opinion in Nephrology and Hypertension 11: 489-496 (22).
Borghi et al. “Use of Lipid-Lowering Drugs and Blood Pressure Control in Patients with Arterial Hypertension” The Journal of Clinical Hypertension 4 (4): 277-285 2002.
Brizzi et al. “Interleukin-3 Stimulates Migration and Proliferation of Vascular Smooth Muscle Cells: A Potential Role in Atherogenesis” Circulation 103: 549-554 (2001).
Chen et al. “Attenuation of Tissue P-Selectin and MCP-1 Expression and Intimal Proliferation by AT Receptor Blockade in Hyperlipidemic Rabbits” Biochemical and Biophysical Research Communications 282:474-479 (2001).
Chen et al. “Cross-Talk Between Dyslipidemia and Renin-angiotensin System and the Role of LOX-1 and MAPK in Atherogenesis Studies With the Combined Use of Rosuvastatin and Candesartan” Atherosclerosis 184 295-301 (2006).
Chen et al. “Direct Effects of Statins on Cells Primarily Involved in Atherosclerosis” Hypertension Research 23: 187-192 (2000).
Chen et al. “Inhibitory Effect of Candesartan and Rosuvastatin on CD40 and MMPs Expression in Apo-E Knockout Mice” J Cardiovasc Pharmacol 44 (4): 446-452 (2004).
Chen et al. “Interaction of Oxidized Low-density Lipoprotein and the Renin-Angiotensin System in Coronary Artery Disease” Current Hypertension Reports 8: 139-143 (2006).
Chen et al. “Marked Upregulation of Lipoxygenase-1, a Receptro for Ox-Low-Density Lipoprotein in Atherosclerosis, and Its Total Ablation by Candesartan and Rosuvastatin Given Concurrently” Journal of the American College of Cardiology 1122-166 498A (2004).
Chen et al. “Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-kB by Losartan in Hypercholesterolemic Rabbits” Journal of Cardiovascular Pharmacology 39: 332-339 (2002).
Chen et al. “Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine” Journal of the American College of Cardiology 30: 569-575 (1997).
Chen et al. “Upregulation of LOX-1 Expression in Aorta of Hypercholesterolemic Rabbits: Modulation by Losartan” Biochemical and Biophysical Research Communications 276: 1100-1104 (2000).
Chiariello, et al. “A Biochemical Method for the Quantitation of Myocardial Scfarring after Experimental Coronary Artery Occlusion” J Mol Coll Cardiol 18: 283-290 (1986).
Chobanian et al. “Influence of Hypertension on Aortic Atherosclerosis in the Wantanabe Rabbit” Hypertension 14: 203-209 (1989).
Crisby et al. “Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization” Circulation 103: 926-933 (2001).
Cyrus et al. “Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis” Circulation 104: 1940-1945 (2001).
J.E. Deanfield “Targeting the Atherosclerotic Process in Clinical Practice. A New Look at Established Agents” Atherosclerosis 165 189-190 (2002).
Faggiotto et al. “Statins and Blockers of the Renin-Angiotensin System Vascular Protection Beyond Their Primary Mode of Action” Hypertension 34 (part 2): 987-996 (1999).
Faia et al. “Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Hamster Aortic Atherosclerosis: Correlation with I
Astrazeneca AB
Betton Timothy E
Morgan & Lewis & Bockius, LLP
Padmanabhan Sreeni
LandOfFree
Therapeutic treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632598